Application of Biomarkers to Clinical Trials in Systemic Sclerosis
- 4 November 2011
- journal article
- review article
- Published by Springer Nature in Current Rheumatology Reports
- Vol. 14 (1) , 47-55
Abstract
Important clinical advances in the treatment of systemic sclerosis have been made, yet fibrotic disease remains largely untreatable. Optimal design of clinical trials to test new therapeutics for fibrotic disease features has suffered from dual difficulties in patient selection and patient evaluation. Patient selection for entry into trials for treatment of interstitial lung disease and/or skin fibrosis is challenged by the natural history of the disease, which stabilizes in some patients while relentlessly progressing in others, and our lack of good clinical markers to distinguish between these trajectories. Patient evaluation is made difficult, particularly in skin disease, by the inherent difficulty in quantifying the extent of disease. Biomarkers hold the potential to solve many of these problems as surrogate outcome measures and as markers for disease progression. Identified biomarkers may have the potential to graduate to surrogate outcome singly or, more likely, in combination. Predictive biomarkers are still largely unknown.Keywords
This publication has 45 references indexed in Scilit:
- Limited Systemic Sclerosis Patients with Pulmonary Arterial Hypertension Show Biomarkers of Inflammation and Vascular InjuryPLOS ONE, 2010
- Osteopontin in the development of systemic sclerosis--relation to disease activity and organ manifestationRheumatology, 2010
- A four‐gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosisArthritis & Rheumatism, 2010
- Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patientsArthritis Research & Therapy, 2009
- Role of breast regression protein 39 (BRP-39)/chitinase 3-like-1 in Th2 and IL-13–induced tissue responses and apoptosisJournal of Experimental Medicine, 2009
- B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosisArthritis & Rheumatism, 2009
- Molecular Subsets in the Gene Expression Signatures of Scleroderma SkinPLOS ONE, 2008
- Serum IL-15 in patients with early systemic sclerosis: a potential novel marker of lung diseaseArthritis Research & Therapy, 2007
- Biomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkClinical Pharmacology & Therapeutics, 2001
- Serum tissue inhibitor of metalloproteinases in patients with systemic sclerosisJournal of the American Academy of Dermatology, 1995